Medical Device Recall Report FY FY 2012

Similar documents
FDA Reauthorization Act of 2017 (FDARA)

FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update

2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations

Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1

Complaint Handling and Medical Device Reporting (MDRs)

Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session

Solutions for GCP Compliance Challenges

FDA Vision for Innovative Surveillance of Orthopedic Implants

STATEMENT. JEFFREY SHUREN, M.D., J.D. Director, Center for Devices and Radiological Health Food and Drug Administration

DOES TECHNOLOGY KEEP PATIENTS OUT OF HOSPITALS?

November 7, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013

Case: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A

Establishment Registration and Device Listing. Michelle C. Jackson, Esq. Partner Venable LLP

Pediatric Medical Device Development and Safety. Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA

GAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees

QA offers significant economic benefits!

510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies

SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office

LCDR Kemi Asante, PharmD, RAC Health Science Policy Analyst Office of Prescription Drug Promotion CDER FDA

CAP Most Frequent Deficiencies and How to Avoid Them. March 11, 2015

MAIMONIDES MEDICAL CENTER. SUBJECT: Medical Equipment Failures and Medical Device Reporting Program

FSMA Update. Samantha Shinbaum. October 3, 2017

Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018

Part 3. Condition of medical equipment

Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements

The Mammography Quality Standards Act Final Regulations Motion of Tube-Image Receptor Assembly

New England District Update FDA s Office of Regulatory Affairs Aligns for the Future

The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements

Medical Devices: Do I Need to Open a CAPA?

FDA HAS MADE PROGRESS

Request to Use an External IRB as an IRB of Record

PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS

Overview of GE Applications & Departments

Texas Tech University Health Sciences Center El Paso

CDRH Device Quality Update March 17, 2015

Investigator Roles and Responsibilities in Clinical Device Trials

SJMHS SAFE MEDICAL DEVICE ACT (SMDA) 7/2017

Received an RTA Deficiency List or AI Letter? Now What?

Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission

An Educational Forum co-sponsored by the. US Food and Drug Administration. and the. FDA Medical Device Industry Coalition

The anesthesiologist switches the patient from the ventilator to the cardiopulmonary

Real-World Evidence: A CDRH Perspective

Guidance for Industry and FDA Staff Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use

Doing Business As name (if applicable): 2. Mailing Address: (Street Address/City/State/Zip) 3. Physical Location: (Street Address/City/State/Zip)

Postmarketing Drug Safety and Inspection Readiness

Authorized Personnel to Review

Better Medical Device Data Yield Improved Care The benefits of a national evaluation system

POSITION DESCRIPTION AND QUALIFICATIONS Water Treatment Plant Operator I

:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France

Guidance for Industry

Chapter 48 - Bioresearch Monitoring

UNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review

Training Update: Preventive Controls Regulator Training


DEPARTMENT OF THE NAVY OFFICE OF THE CHIEF OF NAVAL OPERATIONS 2000 NAVY PENTAGON WASHINGTON, DC

FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7

Compounded Sterile Preparations Pharmacy Content Outline May 2018

Medical Device Reporting for Manufacturers

Connie Hoy October 2013

BIMO Program Update an operational perspective

Software Regulation and Validation

EMERGING TRENDS WHAT I WILL COVER INCREASED INTEREST DEVICES ARE MIGRATING SAFE AND RELIABLE DEVICES LEAD TO LIVING WELL

May 8, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD

Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)

FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV

WIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)

MARYLAND RADIOLOGICAL HEALTH PROGRAM UPDATE

PowerChart Review Guide

Operations Report January, Executive Summary

Manager. 2. To establish procedures for selecting and acquiring biomedical equipment.

CDER Small Business and Industry Assistance (SBIA)

FSMA Enforcement: The First Year

LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.

Food Safety: Agencies Need to Address Gaps in Enforcement and Collaboration to Enhance Safety of Imported Food

THE PREVENTIVE CONTROLS RULES AND THE FSPCA

Definitions: In this chapter, unless the context or subject matter otherwise requires:

CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION DOCUMENT SUBMISSION REQUIREMENTS

Inspections, Compliance, Enforcement, and Criminal Investigations

Optimizing Medical Device Safety: A Closed Loop Process

CLOSE OUT VISIT REPORT (NO CRF TO MONITOR)

FDA s Clinical Trial Inspections in China Including FDA Overall Goals

Consumer Product Safety Commission (CPSC) Enforcement Practices

OSHA's Small Business Resources

2017 MCAFDO Annual Conference

Chapter 1 INTRODUCTION TO FSPCA PREVENTIVE CONTROLS FOR HUMAN FOOD COURSE

IAF Mandatory Document for the Application of ISO/IEC in Medical Device Quality Management Systems (ISO 13485)

NEW CERTIFICATE PROGRAM PROPOSAL. 1. Title: Clinical Training Certificate Program in Clinical Laboratory Science

Pediatric Medical Devices: The FDA Postmarket Perspective

Submitted electronically via: May 20, 2015

Alabama Trauma Center Designation Criteria

The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation

Global Outreach Activity Menu

FSMA Implementation FDA s Preventive Controls Rules

MAIMONIDES MEDICAL CENTER

REGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION

Discussions and Activity at the Federal Level Regarding Management of Electronic Medical Equipment

INFECTION CONTROL SURVEYOR WORKSHEET

Transcription:

Medical Device Recall Report FY 2003- FY 2012 Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health

Questions Why did FDA draft the Medical Device Recall Report? Why has the number of recalls increased since 2003? What types of devices are frequently recalled? And why? What is happening with Class I recalls? Can FDA reduce internal processing times?

WHY the report? FDA Case for Quality (August 2011) GAO report Medical Device Recalls (June 2011) FDASIA Section 605 (July 2012)

Medical Device Recalls 1,200 1,000 800 600 400 200 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Class I 7 24 26 22 26 14 32 49 50 57 Class II 460 466 422 505 540 710 677 753 1152 1043 Class III 183 141 124 132 96 108 67 74 69 90 Totals 650 631 572 659 662 832 776 876 1,271 1,190

Reason #1 for Recall Increases Industry Growth Registered Establishments Medical Device Listings FY2008 19,153 117,618 FY2009 20,270 116,706 FY2010 21,552 129,875 FY2011 23,943 150,307 FY2012 24,133 157,441

Reason #2 for Recall Increases Device Specific Initiatives Addressed high risk and problematic device types across manufacturers AEDs Ventilators Infusion Pumps Radiation Safety

30 25 Number of recalls 20 15 10 Ventilators Radiology AEDS Infusion pumps All 5 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Reason #3 - FDA Inspections Recalls are reported voluntarily by manufacturers About 3,000 device firms are inspected each year How do inspections effect recalls?

Number of Recalls Reported by Firms with 21 CFR 806 Observations ~46 firms receive an 806 citation on a 483 each year Chart shows recalls for these 364 firms After getting dinged, recall reporting improves

Adjusted Recall Counts FY 2003 - FY 2012

WHAT kind of devices? 300 250 200 150 100 Cardiovascular Chemistry General Surgery General Hospital Orthopedics Radiology 50 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Top 10 Procodes in 10 years Recalls Procode Product description Specialty 176 IYE ACCELERATOR, LINEAR, MEDICAL Radiology 153 LLZ SYSTEM, IMAGE PROCESSING, RADIOLOGICAL Radiology 130 FRN PUMP, INFUSION Gen Hospital 115 JAK SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED Radiology 109 MKJ AUTOMATED EXTERNAL DEFIBRILLATORS Cardiovascular 106 GEI ELECTROSURGICAL, CUTTING & COAGULATION & ACCESSORIES Surgery 101 JJE ANALYZER, CHEMISTRY, FOR CLINICAL USE Chemistry 98 JQP CALCULATOR/DATA PROCESSING MODULE, FOR CLINICAL USE Chemistry 97 GKZ COUNTER, DIFFERENTIAL CELL Hematology 96 JWH PROSTHESIS, KNEE, PATELLOFEMOROTIBIAL, SEMI-CONSTRAINED Orthopedic

Recall Reasons

Top Recall Regulatory Violations Number Regulation Subpart Title Class I Class II 820.30 Design controls and related subparts 703 1,759 36 820.80 Receiving, in-process, and finished device acceptance 204 1,068 61 820.70 Production and process controls and subparts 119 830 58 820.90 Nonconforming product 17 415 28 820.75 Process Validation 16 390 30 820.50 Purchasing controls 19 366 29 820.130 Device packaging 0 377 5 820.120 Device labeling and related subparts 2 271 29 820.25 Personnel 0 159 2 820.100 Corrective and preventive action 0 122 7 Class III

Software- related Software Software Change Control Software Design Design (manufacturing process) Sum % of all CDRH Recalls 2008 13 141 2 156 18.3% 2009 9 111 1 121 15.4% 2010 4 73 3 80 8.9% 2011 11 182 10 203 15.8% 2012 12 169 5 186 15.5% Sum/Overall: 49 676 21 746 15.1%

Recalled device time on market 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2004 2005 2006 2007 2008 2009 2010 2011 2012 first 365 days 1 to 5 years 5 to 10 years 10 to 15 years >15 years

Foreign vs Domestic Reporting Figure 19: Proportion of Foreign and Domestic Manufacturer Registration and Recall US % of Mfg Registration Foreign % of Mfg Registration US Mfg % of Recalls Foreign Mfg % of Recalls FY 2010 48.4% 51.6% 81.8% 18.2% FY 2011 47.6% 52.4% 82.7% 17.3% FY 2012 46.7% 53.3% 79.5% 20.5%

What about Class I recalls? Has FDA changed processes? Have manufacturers changed processes? Do devices pose more risk to the public?

Has the risk to patients changed? 100% Class I recalls and Deaths/Injuries 100% Class II recalls and Deaths/Injuries 80% 80% 60% 60% 40% 40% 20% 20% 0% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 0% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Class I w ithout Death or Injuries Class I w ith Injuries only, <5 Class I w ith Injuries only, >5 Class I w ith Death(s) - 75 total Class II w ithout Death or Injuries Class II w ith Injuries only, <5 Class II w ith Injuries only, >5 Class II w ith Death(s) - 2 total

Medical Specialty comparison Class I vs. Class II 90 Class I Class II 1,200 80 70 1,000 60 800 Class I 50 40 30 20 10 600 400 200 Class II 0 HO CV AN CH GU MI SU RA NE OP HE OR EN IM PM DE OB PA TX 0

Examples of Class I recall trends: ventilators and infusion pumps 15 13 11 9 7 5 3 1-1 2003 2004 2004 2006 2007 2008 2009 2010 2011 2012 Aug- 13 Safety Alert 0 0 0 0 1 0 0 0 0 1 0 Class III 1 1 0 0 0 0 0 0 0 1 0 Class II 1 6 6 7 9 9 6 7 11 4 1 Class I 2 1 2 1 0 0 0 2 0 9 9 32 27 22 17 12 7 2-3 2003 2004 2004 2006 2007 2008 2009 2010 2011 2012 Aug- 13 Safety Alert 1 1 1 1 0 0 0 0 0 0 1 Class III 1 0 2 1 1 0 0 0 1 2 0 Class II 6 7 12 11 8 10 12 8 23 10 14 Class I 0 0 3 2 3 1 2 2 8 12 7

Total Recall Times Year Number of Recalls Phase I - Firm awareness to District awareness (mean days) Phase II - District awareness until recommendation sent to CDRH (mean days) Phase III - CDRH receipt to classification and posting (mean days) Phase I - III total recall days to posting (mean days) FY2010 876 85.7 99.7 48.3 233.7 FY2011 1,271 98.2 111.6 37.1 246.9 FY2012 1,190 99.4 135.9 21.3 256.6

On Time Rates FDA Track

Termination Times - CDRH

Report conclusions Recalls increased, mostly due to industry growth, enhanced reporting and specific device type initiatives As demonstrated in device initiative work, FDA and industry can work together to improve device safety for all patients and consumers Analyzing recall data can inform and support pre/postmarket activities and guide resources as well as provide outreach for external stakeholders FDA has improved recall process times and communications in spite of increasing numbers